Humana Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Is HealthStream (HSTM) a Better Healthcare Bet Than Humana (HUM) Right Now?

AI-generated analysis

πŸ“ˆ Humana reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, reaffirming full-year adjusted EPS guidance of at least $9.00.

πŸ“‰ Humana lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36 reflecting non-cash adjustments and value creation charges.

πŸ‘₯ Humana expects individual Medicare Advantage membership to grow approximately 25% in 2026 alongside CenterWell primary care expansion.

⚠️ Lower Star Ratings remain a significant drag on Humana's profitability, with medical benefit ratios reaching 91.2% in Q2.

πŸ“ˆ HealthStream delivered record Q2 2026 results with revenue rising 12.5% year over year to $83.7 million.

πŸ’° HealthStream operating income increased 41.4% to $8.3 million while net income climbed 23.8% to $6.7 million.

πŸ›‘οΈ HealthStream maintains a debt-free balance sheet supported by $66.7 million in cash and cash equivalents.

πŸ”„ HealthStream recurring subscription revenue increased 11.2% in Q2, demonstrating strong SaaS model performance.

🀝 Humana announced a partnership with HealthStream to expand workforce training for caregivers in rural and underserved communities.

🏦 Pzena Investment Management holds 4,403,136 shares of Humana valued at approximately $1.75 billion.

πŸ“ˆ First Eagle Investment Management increased its position in HealthStream by 40% to hold 591,898 shares.

βš–οΈ Investors should watch for stabilization of medical cost ratios at Humana and successful integration of M&A at HealthStream.

Bullish Signals
  • Humana reaffirmed its full-year adjusted EPS guidance of at least $9.00 despite lowering GAAP EPS forecasts due to non-cash adjustments.
  • Individual Medicare Advantage membership is expected to grow approximately 25% in 2026, supporting long-term recovery.
  • Strategic expansion of the CenterWell primary care business and a recent Illinois Medicaid win could strengthen the addressable market.
Risk Factors
  • Lower Star Ratings remain a significant drag on Humana's profitability, potentially squeezing margins further.
  • Elevated medical benefit ratios reached 91.2% in Q2, indicating ongoing pressure on net earnings.
  • Regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds could weigh on future performance.
Full Analysis
Humana Inc. (NYSE: HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, reaffirming full-year adjusted EPS guidance of at least $9.00 while lowering its FY 2026 GAAP EPS forecast to at least $6.52 due to non-cash adjustments and value creation charges. The company expects individual Medicare Advantage membership to grow approximately 25% in 2026, supported by strategic expansion of its CenterWell primary care business and a recent win in Illinois Medicaid. However, profitability faces headwinds from lower Star Ratings and elevated medical benefit ratios that reached 91.2% in the quarter. HealthStream, Inc. (NASDAQ: HSTM) delivered record Q2 2026 results with revenue rising 12.5% year over year to $83.7 million and operating income increasing 41.4% to $8.3 million. The company maintains a debt-free balance sheet supported by $66.7 million in cash, while recurring subscription revenue grew 11.2%. HealthStream is leveraging strategic acquisitions like Virsys12 and MissionCare Collective to capture market share in workforce retention and compliance solutions, though it faces risks related to customer concentration and integration execution. The article contrasts the two companies' trajectories, noting Humana's complex transition involving regulatory pressures versus HealthStream's operational cleanliness and higher growth profile. Hedge fund positioning shows increasing institutional participation in both stocks, with major funds like Pzena Investment Management holding significant positions in Humana and First Eagle increasing stakes in HealthStream. Investors are advised to watch for stabilization of medical cost ratios at Humana and sustained margin expansion from its SaaS model at HealthStream.